Brain Total Creatine Differs Between Primary Progressive Aphasia (PPA) Subtypes and Correlates with Disease Severity

Kathleen E. Hupfeld[a,b], Helge J. Zöllner[a,b], Georg Oeltzschner[a,b], Hayden W. Hyatt[c], Olivia Herrmann[d], Jessica Gallegos[d], Steve C. N. Hui[a,b], Ashley D. Harris[e,f], Richard A. E. Edden[a,b], and Kyrana Tsapkini[d,g*]

[a] Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA

[b] F. M. Kirby Research Center for Functional Brain Imaging, Kennedy Krieger Institute, Baltimore, MD, USA

[c] Department of Physiology, Johns Hopkins University School of Medicine, Baltimore, MD, USA

[d] Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA

[e] Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada

[f] Alberta Children's Hospital Research Institute, University of Calgary, Calgary, Alberta, Canada

[g] Department of Cognitive Science, Johns Hopkins University, Baltimore, MD, USA

Corresponding Author: Kyrana Tsapkini, PhD
Departments of Neurology and Cognitive Science
Johns Hopkins University
Phipps 488, 600 N Wolfe Street
Baltimore, MD 21287
Email: tsapkini@jhmi.edu

Running Title: BRAIN CREATINE IN PRIMARY PROGRESSIVE APHASIA

Abstract

Background: Primary progressive aphasia (PPA) is a debilitating neurodegenerative disease

that primarily impairs language function. It is comprised of three subtypes with varied clinical

presentation and cortical atrophy patterns: logopenic variant (lvPPA), non-fluent variant

(nfvPPA), and semantic variant (svPPA). No prior work has examined differences in brain

chemistry between the PPA subtypes, or associations of brain chemistry with symptom severity.

Methods: We collected magnetic resonance spectroscopy (MRS) data in the left inferior frontal

gyrus (IFG, a main language production region) and the right sensorimotor cortex (SMC) from

61 PPA patients. We analyzed tissue-corrected metabolite levels to account for the effects of

cortical atrophy and other tissue-specific properties. We aimed to: 1) characterize differences

between PPA subtypes for 5 brain metabolites: total N-acetylaspartate (tNAA), total choline

(tCho), total creatine (tCr), glutamate+glutamine (Glx), and gamma-aminobutyric acid (GABA);

and 2) test for associations between these neurometabolites and PPA symptom severity.

Results: tCr levels differed by PPA subtype across both the left IFG and right SMC. In both

regions, tCr levels were lowest among lvPPA patients and highest among svPPA patients.

Moreover, across the whole cohort, higher tCr and lower Glx levels in the left IFG correlated

with greater disease severity.

Conclusions: Given that tCr is involved in brain energy metabolism and homeostasis, our

results indicate that svPPA pathology might involve changes in specific cellular energy

processes. Moreover, our finding that higher tCr was associated with worse PPA symptom

severity suggests that perturbations to cellular energy homeostasis in cortical language areas

may contribute to PPA symptoms. In addition, reduced cortical excitatory capacity (i.e., lower

Glx) in brain areas related to language processing may also contribute to PPA symptoms.

Together, these findings suggest that tCr could serve as a biomarker to differentiate between

PPA subtypes, and that both tCr and Glx might have utility for better understanding PPA

disease mechanisms and tracking disease progression.

Trial registration: ClinicalTrials.gov (NCT02606422). Registered 11 November 2015 -

Retrospectively registered,

https://clinicaltrials.gov/ct2/show/NCT02606422?term=NCT02606422&draw=2&rank=1

Keywords: Primary Progressive Aphasia (PPA), creatine (tCr), glutamate+glutamine (Glx),

magnetic resonance spectroscopy (MRS), Point RESolved Spectroscopy (PRESS)

1. Background

Primary progressive aphasia (PPA) is a devastating neurodegenerative condition

characterized by prominent declines in language function (1,2). Symptoms usually begin in

middle age (around 40-60 years), worsen over time, and may later extend to other cognitive

domains (1–3). PPA thus considerably impacts quality of life, in addition to shortening life

expectancy; average life expectancy after PPA diagnosis is only about 3-12 years (4). Critically,

aside from some symptom improvement with behavioral therapy (5) or neuromodulation (6,7),

there remain no disease-modifying treatments for PPA. Therefore, it is becoming increasingly

imperative to improve scientific understanding of PPA pathology to identify biomarkers of

disease progression as well as potential therapeutic targets.

Consistent with their language symptoms, those with PPA typically display cortical

atrophy in the left hemisphere, particularly in brain regions related to language function (8).

However, PPA is a heterogeneous disorder associated with both varied symptoms and varied

pathology. As such, expert consensus has divided PPA into three subtypes (1) (along with

mixed or unclassified cases): 1) logopenic variant PPA (lvPPA) is characterized by deficits in

word retrieval (i.e., producing the intended word) and difficulty repeating words and sentences;

2) non-fluent variant PPA (nfvPPA) is characterized by deficits in grammar and speech

production and slow, effortful, and distorted (apraxic) speech, but preserved word

comprehension and naming; and 3) semantic variant PPA (svPPA) is characterized by severe

deficits in single-word comprehension and naming, but preserved grammar and fluency (i.e.,

these individuals tend to produce "empty" speech).

These three subtypes have been linked to different cortical atrophy patterns and different

pathology. Atrophy is most prominent in the left posterior temporal and inferior parietal lobes in

lvPPA, left posterior frontal and fronto-insular cortex in nfvPPA, and anterior temporal lobes (left

dominant but usually bilateral) in svPPA (1). lvPPA is most often associated with Alzheimer's

disease (AD) pathology (e.g., PET-PIB positivity, decreased Aβ42, and elevated tau in the

cerebrospinal fluid) (9,10), nfvPPA is most often associated with tau-positive pathology

(9,11,12), and svPPA is most often associated with ubiquitin/TDP43-positive frontotemporal

lobar degeneration (3,9,13–15). However, there is not a direct correspondence between atrophy

or pathology and PPA subtype; thus, further work is warranted to better understand how

disease mechanisms might differ between the PPA subtypes.

Magnetic resonance spectroscopy (MRS) permits measurement of brain chemicals *in*

vivo in humans using an MRI scanner and thus can provide insight into potential disease

mechanisms and drug targets, distinct from conclusions that can be drawn from the atrophy and

pathology measurements discussed above. Standard MRS acquisitions, including short-echo

time (TE) Point RESolved Spectroscopy (PRESS), measure metabolites including total *N*-acetyl

aspartate (tNAA), total choline (tCho), total creatine (tCr), and glutamate+glutamine (Glx) (16).

tNAA, a composite measure of NAA and NAAG (N-acetylaspartylglutamate), is a neuronal

marker, suggested as an indicator of neuronal density and integrity (17). tCho, the composite of

phospholipid precursors phosphocholine (PCh) and glycerophosphocholine (GPC), can reflect

changes in membrane turnover or cell density (18). Creatine and phosphocreatine (reported in

combination as tCr) are involved in brain energy metabolism and homeostasis (17). Glx is a

combination of two signals: glutamate (i.e., the principal excitatory neurotransmitter in the

central nervous system (CNS)) and glutamine (i.e., a precursor for glutamate). *J*-difference

editing of the spectrum using e.g., MEscher–GArwood Point RESolved Spectroscopy (MEGA-

PRESS) (19–21) allows us to quantify additional metabolites with coupled spin systems and

overlapped signals. These include the primary inhibitory neurotransmitter within the CNS,

gamma-aminobutyric acid (GABA).

A majority of studies suggest that brain tNAA, Glx (or glutamate), and GABA levels

decrease with normal aging (18,22–24), and are decreased in mild cognitive impairment (MCI)

(25,26) and AD (27–30) compared with normal aging. Both tCho and tCr either increase or show

no change with normal aging (18,22,24), and are either elevated (31,32) or not different (29,32)

in MCI and AD compared with normal aging. Functionally, lower MRS-measured tNAA, Glx (or

glutamate), and GABA, and higher tCho, have each been associated with poorer cognitive

performance in normal aging (33–37), MCI (25,38–40), AD (39), and frontotemporal lobar

degeneration patients (41). Taken together, it is plausible that these metabolites might differ

between the three PPA subtypes and associate with metrics of disease severity.

130   We previously identified GABA decreases in the left inferior frontal gyrus (IFG) following

transcranial direct current stimulation (tDCS) combined with language therapy in PPA patients

(42). However, the sample size included in this prior work (n = 22) was not sufficient to stratify

metabolite level differences by the three PPA subtypes. Therefore, the objectives of the present

study included: 1) to characterize differences in brain metabolite levels between the three PPA

subtypes; and 2) to examine relationships between brain metabolite levels and PPA symptom

severity, as indicated by the FrontoTemporal Dementia Clinical Dementia Rating Scale (FTD-

CDR, a measure of overall disease severity, including language function, memory, attention,

and independence, with scores ranging from 0 (no impairment) to 24 (severe impairment) (43)).

2. Methods

2.1 Participants

142   Prior to study enrollment, all patients were evaluated using neurological examination,

cognitive and language testing, and neuroimaging. All patients enrolled in the study were

diagnosed with PPA using current consensus criteria (1); diagnoses were confirmed by expert

clinicians. Additional inclusion criteria included: at least a 12th grade education, right-

handedness, and English as a first language. Participants were excluded if: they were over 90

years of age, were not pre-morbidly proficient spellers, had progressed to advanced stages of

PPA or other dementia, had any diagnosed comorbid neurologic conditions (e.g., stroke,

psychiatric, or developmental disorder), or if they had any contraindications for MRI scanning.

The Johns Hopkins University Institutional Review Board (#NA_00071337) approved all study

procedures, and the trial was registered on ClinicalTrials.gov (NCT02606422). All participants

scored >0 on the FTD-CDR scale, indicating at least some level of impairment to daily

functioning.

2.2 MRS Acquisition

All MRS data were collected using the same 3.0 Tesla Philips Achieva MRI scanner

using a 32-channel head coil. For voxel positioning and tissue segmentation, we collected a

whole-brain T_1-weighted structural MRI scan, using the following parameters: magnetization-

prepared rapid gradient-echo (MPRAGE) sequence, TR/TE = 8 ms/3.75 ms, flip angle = 8°,

slice thickness = 1.0 mm, 150 slices, voxel size = 1 mm^3 isotropic voxels. Next, we acquired

metabolite spectra from two 30 x 30 x 30 mm^3 voxels (Fig. 1) using both short-TE PRESS and

MEGA-PRESS sequences. We positioned the left IFG voxel using the anatomical landmarks of

the lateral ventricles and insula. We positioned the right SMC voxel by centering the voxel on

the hand knob in the precentral gyrus. Both voxels were carefully shifted and rotated to avoid

the edge of the brain and ventricles as much as possible to avoid lipid contamination and

partial-volume effects.

To measure tNAA, tCho, tCr, and Glx, we used a standard short-TE PRESS acquisition

with the following parameters: TR/TE = 2000 ms/32 ms; 48 averages sampled at 2000 Hz with

2048 points; and water suppression using the VAPOR method (44). To resolve GABA, we used

MEGA-PRESS (20,21) with the following parameters: TR/TE = 2000 ms/68 ms; 14-ms editing

pulses at 1.9 ppm and 7.46 ppm, alternating every 2 averages; 320 averages in total; and

VAPOR water suppression (44). MEGA-PRESS editing schemes for the detection of GABA co-

edits homocarnosine and macromolecular signals (45); therefore, as is standard practice, we

refer to the edited 3 ppm GABA signal as GABA+ in the remainder of the manuscript. For both

the short-TE PRESS and MEGA-PRESS acquisitions, we also collected 8 water reference

spectra without water suppression or pre-inversion, for later use in eddy current correction and

metabolite quantification.

Fig 1. Voxel Placement and Spectra. (A) *In vivo* MR spectra were acquired from the left inferior frontal gyrus (IFG) and right sensorimotor cortex (SMC); here we depict the placement of both voxels (IFG in green, SMC in blue) for a single exemplar participant overlaid onto their skull-stripped structural image to protect patient privacy. The rendered structural image is shown as semi-transparent, in order to depict voxel placement within the brain. **(B-C)** Average short-TE PRESS and GABA-edited MEGA-PRESS spectra (black), 95% confidence interval (gray shading) and model fits (blue) for all participants for both voxels. The PRESS spectra are shown from 0.2-4.2 ppm. The MEGA-PRESS spectra are shown from 2.7-4.2 ppm.

2.3 MRS Data Processing

MRS data were analyzed using the open-source analysis toolbox Osprey (v2.0.0; https://github.com/schorschinho/osprey/) (46) within MATLAB R2021b. The analysis procedures followed consensus-recommended processing guidelines for PRESS and MEGA-PRESS data (19,47) and match those applied in our previous work (48,49). Briefly, for the short-TE PRESS data, analysis steps included: loading the vendor-native raw data (which had already been coil-combined, eddy-current-corrected, and averaged on the scanner at the time of data collection), removing the residual water signal using a Hankel singular value decomposition (HSVD) filter (50), and modeling the metabolite peaks as described in detail in (46,48) using a custom basis set generated by our new MRSCloud tool (https://braingps.anatomyworks.org/mrs-cloud; (51)).

The basis set was generated using PRESS localization at TE = 32 ms with the Philips-specific

sequence timing and real RF pulse waveforms, and consisted of simulations of 32 metabolites

including NAA and NAAG (=tNAA), Cr and PCr (=tCr), GPC and PCh (=tCho), Glu and Gln

(=Glx), and GABA (which are of interest in this study), as well as 23 other low-concentration

metabolites. We then created a binary mask of the two MRS voxels in subject space, co-

registered these masks to each participant's T_1-weighted structural scan, and segmented the

structural scans using SPM12 (52), and quantified metabolite levels with respect to the

unsuppressed water scan. These tissue volume fractions in the MRS voxels were used for full

tissue- and relaxation-corrected metabolite quantification (see below).

For the GABA-edited MEGA-PRESS data additional, standardized analysis steps in

Osprey included: eddy-current correction based on the water reference (53), robust spectral

registration (54) to separately align the individual transients within each sub-spectrum, and final

alignment of the averaged sub-spectra by minimizing the choline peak in the difference

spectrum before generating the final GABA-edited difference spectrum. The co-edited

macromolecules (MMs) at 3 ppm were modelled with the "1to1GABA" model, which uses one

composite GABA + MM basis function (i.e., the sum of the GABA and MM_{3co} basis functions,

with a fixed 1:1 amplitude ratio); this model assumes 50% of the 3-ppm signal in the GABA-

edited difference spectrum can be attributed to co-edited MMs (49,55). As is standard for 3 T

GABA-edited MEGA-PRESS data, we considered the composite edited 3-ppm signal, i.e.,

"GABA+" (GABA+MM) values in our statistical analyses.

Finally, we corrected all metabolite estimates in order to assess metabolite levels only in

the tissue present in the voxel, which is particularly relevant for aging and neurodegenerative

disease populations who may have substantial cortical atrophy (56). We applied tissue and

relaxation correction to the short-TE PRESS values; this adjusts metabolite estimates to

account for atrophy and heterogeneous tissue composition within the voxels, using literature

values (57) to account for differences in water visibility and relaxation times between tissue

types (58,59). Similarly, to account for the effects of atrophy and tissue-specific water visibility

and relaxation, (and assuming that GABA+ levels in gray matter are twice that in white matter),

we applied the "alpha" correction to all GABA+ values (59). For further details, see Appendix A,

in which we list all consensus-recommended parameters regarding our MRS data acquisition,

processing, and quality (60).

2.4 Statistical Analyses

We conducted all statistical analyses using R 4.0.0 (61) within RStudio (62). First, we

used one-way ANOVAs (or Kruskal-Wallis non-parametric tests if the ANOVA assumptions of

normality and heteroskedasticity were not met) to test for group differences in demographic

variables and symptom severity between the three subtypes. Next, we used linear mixed

models (*lme*, (63)) to examine whether metabolite levels differed by PPA subtype or brain

region. In the final model, we entered the metabolite level as the outcome variable, PPA

subtype and voxel (i.e., IFG or SMC) as predictors, and included a random intercept for each

subject (similar to our previous work, (64)). Including the PPA subtype*voxel interaction term or

a random slope for each subject did not improve model fit (likelihood ratio test $p > 0.05$), so

these terms were omitted from the final statistical models. Each final model satisfied the linear

mixed model assumptions of homogeneity of variances and normality of residuals. We used this

same linear mixed model approach to test for PPA subtype and brain region differences in bulk

tissue composition (i.e., voxel gray matter, white matter, and cerebrospinal fluid fractions).

Lastly, we applied a linear model to test for relationships between brain metabolite levels

and PPA symptom severity (i.e., FTD-CDR scores). Given the subgroup sizes and the missing

MRS and FTD-CDR data (see Table B1), we conducted this analysis across the whole cohort

instead of stratified by PPA subtype. In addition, given the amount of missing GABA+ data

compared with the other metabolites (Table B1), we did not include GABA+ as a predictor in this

metabolite-symptom severity model (though we did test for GABA+ differences between PPA

subtypes, as described above). Thus, in the full model, we entered as predictors: the metabolite

levels from both voxels (4 metabolites/voxel), age, sex, and years since diagnosis. We then

selected a final model using *bestglm* with cross-validation, delete-d method, and 1,000

replications to produce a final model that retained only the best predictors of FTD-CDR score

(65,66). The FTD-CDR scores were not normally distributed (Shapiro test $p < 0.05$), so we reran

the same model selection procedure after square root-transforming the FTD-CDR variable,

which improved the normality of the data (Shapiro test $p > 0.05$).

254
3. Results

3.1 Sample Characteristics

The total cohort consisted of 61 PPA patients: 22 nfvPPA, 27 lvPPA, and 12 svPPA.

There were no differences in sex, age, time since diagnosis, or symptom severity based on PPA

subtype (Table 1). IFG short-TE PRESS data was not collected for 2 participants, IFG MEGA-

PRESS data was not collected for 1 participant, and FTD-CDR scores were missing for 7

participants. Table B1 details additional data omissions from statistical analyses; MRS data

were excluded if NAA linewidth was greater than 15 Hz (47) or if incorrect pulse sequence

parameters were used during acquisition. Group mean spectra (after these exclusions) are

presented in Fig. 1, and data quality metrics (i.e., linewidth, SNR, and fit error) are presented in

Appendix A.

Table 1. Sample Characteristics

	lvPPA	nfvPPA	svPPA	F or χ^2	p	η^2
n	22	27	12	--	--	--
Sex	13 F; 9 M	11 F; 16 M	7 F; 5 M	1.97	0.373	--
Age (years)	65.58 (8.11)	68.65 (6.61)	69.07 (5.16)	1.50	0.231	0.05
Years of education[a,b]	16.48 (1.91)	16.83 (2.44)	16.35 (2.33)	0.23	0.799	0.01
Years since diagnosis[a,c]	3.93 (2.83)	3.81 (2.58)	5.05 (2.91)	0.83	0.442	0.03
FTD-CDR sum score[a,d]	6.55 (5.17)	5.26 (4.17)	7.61 (5.59)	0.87	0.424	0.03

Table 1 Note. For each metric, we report the mean (standard deviation) for each PPA subtype. We also report the results of one-way ANOVAs to characterize differences in each variable between the subtype groups. For sex, we report the number of males (M) and females (F) and the result of a Pearson's chi-square test for differences in the sex distribution within each group. This table includes all available participants; however, statistical analyses of MRS data omitted several additional participants (see Table B1).

[a] In cases where the variable did not meet the one-way ANOVA assumptions of homogeneity of variances between groups, independence of residuals, and/or normality of residuals (indicated by the subscript 'a'), we reran each analysis using the non-parametric Kruskal-Wallis test. In all cases, the non-parametric test did not change the statistical significance of the result.

[b] Years of education was unavailable for 1 lvPPA, 3 nfvPPA, and 2 svPPA patients.

[c] Years since diagnosis was unavailable for 1 lvPPA, 3 nfvPPA, and 1 svPPA patients.

[d] FTD-CDR sum score was unavailable for 4 nfvPPA patients and 3 svPPA patients.

3.2 Differences in Brain Metabolite Levels by PPA Subtype

tCr levels differed by subtype across both voxels; svPPA patients had higher mean tCr compared with lvPPA patients (*p* = 0.019; Fig. 2; Table 2). nfvPPA patients had higher mean tCr levels compared with lvPPA patients, though this difference did not reach statistical significance within the linear mixed effects model (*p* = 0.071; Fig. 2; Table 2). There were no other differences in brain metabolite levels (all *p* > 0.05; Fig. 2; Table 2) or voxel tissue fractions (all *p* > 0.05; Table B3) based on PPA subtype.

3.3 Regional Differences in Brain Metabolites and Voxel Composition

tNAA was lower in the IFG compared with the SMC voxel (*p* < 0.001), while tCho, tCr, and Glx were higher in the IFG compared with the SMC voxel (all *p* < 0.001; Fig. 2; Table 2). GABA+ did not differ by brain region (*p* = 0.626; Fig. 2; Table 2). The IFG compared with the SMC voxel had a higher gray matter (*p* < 0.001) and lower white matter fraction (*p* < 0.001), as well as a greater total tissue fraction (i.e., higher gray matter + white matter fraction; *p* = 0.012; Table B3).

301
302
303 **Fig 2. Differences in Metabolites by PPA Subtype and Brain Region.** Metabolite levels for the lvPPA (pink),
304 nfvPPA (green), and svPPA (blue) subtypes are shown for the IFG (left) and SMC (right) voxels.
305 * indicates $p < 0.05$ for the comparison of svPPA tCr levels with lvPPA tCr levels.
306 *** indicates $p < 0.001$ for the comparison of metabolite values within the SMC versus the IFG.

308 **Table 2.** Differences in Metabolites by PPA Subtype and Brain Region
309

Predictors	Estimates (SE)	CI	t	p
tNAA (i.u.)				
Diagnosis *(nfvPPA)*	-0.53 (0.33)	-1.19-0.12	-1.60	0.115
Diagnosis *(svPPA)*	-0.17 (0.41)	-0.98-0.64	-0.41	0.684
Voxel *(SMC)*	2.58 (0.19)	2.20-2.95	13.44	**< 0.001***
tCho (i.u.)				
Diagnosis *(nfvPPA)*	0.11 (0.09)	-0.07-0.28	1.22	0.227
Diagnosis *(svPPA)*	-0.12 (0.11)	-0.34-0.09	-1.12	0.269
Voxel *(SMC)*	-0.26 (0.05)	-0.35-(-0.16)	-5.38	**< 0.001***
tCr (i.u.)				
Diagnosis *(nfvPPA)*	0.34 (0.18)	-0.02-0.69	1.84	0.071
Diagnosis *(svPPA)*	0.54 (0.23)	0.10-0.99	2.40	**0.019***
Voxel *(SMC)*	-0.40 (0.11)	-0.61-(-0.19)	-3.78	**< 0.001***
Glx (i.u.)				
Diagnosis *(nfvPPA)*	0.91 (0.60)	-0.27-2.09	1.51	0.136
Diagnosis *(svPPA)*	0.01 (0.74)	-1.45-1.47	0.01	0.988
Voxel *(SMC)*	-2.58 (0.33)	-3.23-(-1.93)	-7.79	**< 0.001***
GABA+ (i.u.)				
Diagnosis *(nfvPPA)*	-0.10 (0.28)	-0.65-0.45	-0.37	0.716
Diagnosis *(svPPA)*	0.10 (0.36)	-0.60-0.80	0.28	0.782
Voxel *(SMC)*	-0.11 (0.23)	-0.57-0.34	-0.49	0.626

310
Table 2 Note. Here we report the results of a linear mixed effects model testing for PPA subtype and voxel
differences in each metabolite. lvPPA and IFG served as the reference groups. For ease of interpretation, in this table
we included only the predictors of interest; see Table B2 for all model and fit information. SE = standard error; CI =
95% confidence interval. *$p < 0.05$, ***$p < 0.001$.

3.4 Metabolite Relationships with PPA Symptom Severity

We included all short-TE PRESS metabolite levels from both voxels (i.e., 4

measures/voxel), age, sex, and years since diagnosis in the full statistical model, and only those

participants without missing short-TE PRESS or FTD-CDR data (*n* = 49; see Table B1). The

final model retained left IFG tCr, left IFG Glx, and years since diagnosis as statistically

significant predictors of FTD-CDR score (Table 3). That is, across the whole cohort, worse PPA

symptoms (i.e., higher FTD-CDR scores) were associated with higher left IFG tCr levels (partial

r = 0.39; *p* = 0.007; Fig. 3A), lower left IFG Glx levels (partial r = -0.36; *p* = 0.012; Fig. 3B), and

longer disease duration (partial r = 0.34; *p* = 0.021). Rerunning this model with the square root

of FTD-CDR scores as the outcome variable (to meet the normality assumption) returned the

same three predictors and did not change the statistical significance of any results.

Fig 3. Relationship of IFG tCr and Glx with FTD-CDR Score. This figure depicts the partial correlations of tCr and
Glx levels in the left IFG with FTD-CDR scores across all participants (indicated by each gray point). These partial
correlations account for the effects of the other predictors included in the final statistical model on the variable of
interest (i.e., tCr values are corrected for Glx and years since diagnosis, and Glx values are corrected for tCr and
years since diagnosis). Higher FTD-CDR scores indicate worse PPA symptom severity. These plots include *n* = 49
individuals, after exclusion of missing and unusable data (see Table B1).

Table 3. Metabolites Relationships with PPA Symptom Severity

Predictors	Estimates (SE)	CI	t	p	R^2 / R^2 Adjusted
(Intercept)	-14.18 (9.19)	-32.69-4.32	-1.54	0.130	
IFG tCr (i.u.)	1.96 (0.69)	0.57-3.35	2.84	**0.007****	
IFG Glx (i.u.)	-0.55 (0.21)	-0.98-(-0.13)	-2.61	**0.012***	
Years since diagnosis	0.48 (0.20)	0.08-0.89	2.39	**0.021***	
					0.34 / 0.29

Table 3 Note. Here we report the results of the final linear model testing for associations between brain metabolite levels and FTD-CDR (i.e., PPA symptom severity) scores. SE = standard error; CI = 95% confidence interval. *$p < 0.05$, **$p < 0.01$.

4. Discussion

This is the first study to investigate brain metabolite differences between PPA subtypes using MRS. Our key findings included, firstly, that tissue-corrected tCr differed by PPA subtype across the left IFG and right SMC; lvPPA patients had the lowest tCr levels, followed by nfvPPA, and svPPA patients with the highest brain tCr levels. Secondly, higher tissue-corrected tCr and lower Glx levels in the left IFG (i.e., a brain region critical for language function) were associated with more severe symptoms as indicated by the FTD-CTR scale (which indexes language function as well as other cognitive and daily living domains (43)). Together, these results suggest that brain tCr may play a role in PPA pathology or progression, particularly for the svPPA subtype, and thus could have utility for differentiating svPPA from other PPA subtypes. Both tCr and Glx might be explored as biomarkers for tracking disease severity and progression.

Those with svPPA had the highest tCr levels across both the left IFG and right SMC. The creatine (Cr)/phosphocreatine (PCr) system is a short-lived energetic system that allows exchange of high-energy phosphate between Cr, adenosine triphosphate (ATP), and adenosine diphosphate (ADP). Creatine kinase, the primary enzyme in the Cr system, reversibly exchanges high-energy phosphate between ATP and Cr (forming PCr) or PCr and ADP (forming ATP). In doing so, the Cr/PCr system simultaneously supplies a high-energy pool capable of rapidly regenerating ATP during high energetic demands, while also dispersing ATP across the cell to connect ATP consumption to the site of energy production (i.e., a bucket-

brigade of ATP dispersion (67)). Cr is found in the highest concentrations in tissues with high

ATP demand, including muscle and brain tissue (17,68). MRS at 3 T permits measurement of

tCr (i.e., the sum of Cr and PCr); tCr is thus reflective of the Cr/PCr system more generally,

including PCr anabolism (via Cr synthesis enzymes glycine amidinotransferase (AGAT) and

guanidinoacetate methyltransferase (GAMT)), Cr degradation (non-enzymatic conversion to

creatinine), and Cr extracellular transport (via Cr transporter, SLC6A8).

Previous MRS studies have reported elevated tCr in normal aging (18,22,24,69–72),

MCI and AD (31), and other neurological conditions with cognitive symptoms (e.g., HIV-positive

patients with neurological symptoms (73,74)). It remains unclear whether this is due to

increased Cr and/or PCr synthesis, or decreased clearance of these metabolites from the brain

(71). It is hypothesized that elevated brain tCr is related to declines in creatine kinase activity

with aging and neurological disease (22,69,70,75–77), possibly due to elevated oxidative stress

(67,78). In the present work, it could be that svPPA patients encounter the greatest oxidative

stress and resulting perturbation to Cr/PCr cellular energy processes. Future MRS studies that

edit for antioxidant levels (e.g., glutathione and ascorbate, (79)) could better elucidate potential

contributions of declining antioxidant systems to PPA disease processes.

It is also plausible that elevated levels of tCr could be a compensatory mechanism for

reduced mitochondrial trafficking in neurons of svPPA individuals. Mitochondrial trafficking

refers to the movement of mitochondrial organelles across the cell. Due to the large length of

axonal projections in neurons, new mitochondria arising from mitochondrial biogenesis must be

delivered from the soma to distal axons (80). Once arrived, mitochondria are anchored in the

cell by the protein syntaphilin (SNPH), which abolishes the movement of mitochondria (81).

Notably, a recent report showed that SNPH was significantly elevated in a cohort of individuals

with TDP43-positive frontotemporal lobar degeneration (82), which is the pathology most

associated with the svPPA subtype (1). In this manner, elevated SNPH could result in

decreased mitochondrial motility, resulting in a greater need to disperse high-energy phosphate

across the cell from sites of production (e.g., mitochondria) to sites of energy consumption (e.g.,

neuronal synapses). In this regard, elevated Cr may compensate for an inability to appropriately

localize mitochondria across neurons and allow for transport of high-energy phosphate across

Cr molecules via creatine kinase. In support of this, neurons lacking appropriate mitochondrial

trafficking machinery have markedly reduced ability to form long dendrites; however, this is

rescued with Cr supplementation (83). Finally, mitochondrial trafficking has been observed to

decrease with older age in animal models (84,85), which may also contribute to reports of

elevated brain tCr with aging (18,22,24,69–72). Nonetheless, our understanding of both svPPA

pathology and mitochondrial trafficking remain incomplete, and further work is needed to better

understand potential mitochondrial trafficking deficiencies and relationships with brain tCr levels.

397   Some authors have suggested that elevated tCr in aging and neurologic disease

represent gliosis (69,86,87), as glial cell concentration of tCr is about two to four times that of

neurons (88), and prior work has found elevated tCr levels in non-human primates with

moderate compared to mild gliosis (87). PPA is associated with a significant accumulation of

activated microglia in both gray (89) and white matter (90), particularly in heavily atrophied

regions of the language-dominant hemisphere (89,90). Microglia (i.e., the macrophages of the

brain) become "activated" in response to neuronal damage, inflammation, and other brain

pathology (91,92). This thus fits with our finding of higher tCr levels in the left IFG (i.e., the more

affected language cortex in PPA) compared with the right SMC. In addition, activated microglia

have been reported to occur close to pathologic insults such as TDP43 inclusions in PPA

patients with TDP43-positive pathology (89), i.e., the pathology most associated with svPPA (1).

408   Moreover, it is interesting that tCr levels were the highest in svPPA, as this PPA subtype

is typically associated with the most severe behavioral disturbances (93,94) (though we did not

find group differences in symptom severity; however, the svPPA group had the most severe

average symptom scores). In addition to the potential explanations for elevated tCr levels

described above, other prior work has found the most widespread, bilateral cortical atrophy for

svPPA patients (1). Therefore, though the metabolite estimations presented here are corrected

for cortical atrophy, greater atrophy in svPPA still suggests that more of the brain is affected by

disease processes compared with the other two PPA subtypes. However, there remain very few

studies describing brain differences between PPA subtypes; thus, it is difficult to closely

compare the present findings with past work.

We found that both higher tCr and lower Glx levels correlated with more severe PPA

symptoms, as indicated by the FTD-CDR inventory. This suggests that higher brain tCr and

lower brain Glx levels could be (directly or indirectly) related to maladaptive disease processes.

These brain-behavior relationships occurred only for the left IFG but not the right SMC. The

regional specificity of this association is plausible (and was hypothesized), as the FTD-CDR

inventory includes both language and cognitive function sections; the left IFG is involved in

language selection and production (e.g., both oral and written naming and spelling) and

cognition (e.g., articulatory loop in working memory) (95), while the SMC roles are mostly

related to motor execution and sensory processing. Higher tCr levels might indicate disruptions

in underlying cellular bioenergetic processes, which could contribute to the development of

more severe language and cognitive symptoms in PPA patients; however, such claims warrant

further replication in future studies with larger samples, as well as exploration of tCr

relationships with additional cognitive metrics.

While we found that elevated brain tCr levels correlated with the most severe PPA

symptoms, and others have reported elevated tCr in AD (31), higher brain tCr levels might not

be entirely dysfunctional; the relationship between tCr levels and PPA disease processes could

be more complex. For instance, oral Cr supplementation has been shown to improve cognitive

function in normal adults (96) (though results were variable dependent on cognitive domain,

effect sizes were small-moderate, and no large-scale Cr supplementation studies have been

conducted in PPA patients). Moreover, multiple prior studies have reported *lower* tCr levels or

no difference in tCr levels for normal aging cohorts (18). While these studies used varying

methods (e.g., different MRI scanner field strengths and different brain regions), it remains

unclear what other factors might influence brain tCr changes in aging and disease.

Prior work has identified relationships between lower Glx (or glutamate) and poorer

cognitive and visuomotor performance in both normal aging (97,98) and neurodegenerative

disease (i.e., MCI (25,26) and frontotemporal lobar degeneration (41,99)). Reduced Glx could

indicate loss of glutamatergic neurons or disturbances in glutamate and/or glutamine synthesis,

which could each reasonably contribute to poorer functional performance. Moreover, as

glutamate is a component involved in the synthesis of glutathione (i.e., one of the most

abundant brain antioxidants), it could also be that increased brain oxidative stress in response

to disease processes would result in greater glutathione production (64,100), and thus lower

detectable brain glutamate levels. In our cohort, tCr was not correlated with Glx levels in either

the IFG (Pearson r = -0.04; p = 0.782) or SMC (Pearson r = 0.13; p = 0.383), and thus each

metabolite may distinctly contribute (directly or indirectly) to PPA disease processes. Further

investigation is warranted to better understand the precise mechanisms by which tCr and Glx

might associate with PPA symptoms and progression.

We identified differences in brain metabolite levels by PPA subtype only for tCr, but not

for the other four investigated metabolites. The metabolite values reported here are corrected

for bulk tissue concentrations (58,59); that is, we report metabolite values only within the brain

tissue that remains in the voxels, accounting for age-related atrophy of gray and white matter.

Therefore, though the three PPA subtypes are associated with differing cortical atrophy patterns

(1), our results are not likely explained by group differences in atrophy location and severity.

Moreover, as we did not identify group differences in tNAA levels, it is less likely that the tCr

group difference is driven by diffuse neuronal loss; instead, we predict that these group

differences in tCr are more related to differences in brain energy metabolism, though this

hypothesis warrants further investigation in larger cohorts.

There are several limitations to this work. Our cross-sectional approach precluded us

from assessing how these metabolite levels may alter prior to PPA onset and with disease

progression. Though both age and years since diagnosis did not differ between PPA subtypes,

and years since diagnosis was distinct from the relationships between IFG tCr and Glx and

symptom severity, it still could be that disease progression rather than subtype more strongly

influences brain metabolite levels. PPA is relatively rare and difficult to diagnose (43); thus, we

could not compare individuals at the same stage in their disease progression. Brain metabolite

levels for one or more subtypes may not differ substantially from normal aging; however, due to

the lack of a normal aging control group, we were unable to determine this. There were no

differences in the relationship between tCr and symptom severity based on PPA subtype,

though all groups trended in the same direction; however, we were likely underpowered to

investigate any group differences in this brain-behavior relationship. In addition, there are

several inherent limitations to the MRS methods used. Current methods do not allow us to

distinguish the contribution of PCr versus Cr to the tCr signal, or the contribution of glutamate

versus glutamine to the Glx signal. The tissue corrections applied here are standard for aging

cohorts with cortical atrophy (58,59); however, these corrections use literature values (57) for

relaxation constants. Changes in water and metabolite relaxation rates with aging and disease

could also impact metabolite quantification (101–103), though these were not quantified and

thus cannot be incorporated into tissue corrections. Finally, PPA patients often have more

difficulty than others remaining still in the scanner, which could have affected spectral quality

(though we excluded any participants with NAA linewidth > 15 Hz); moreover, ability to complete

an MRI scan precluded us from enrolling any extremely advanced PPA cases in this cohort.

5. Conclusions

We found that brain tCr is different between PPA subtypes (i.e., the highest for svPPA

patients). We also found a correlation between both higher left IFG tCr levels and lower left IFG

Glx levels and more severe PPA symptoms. tCr could be useful in differentiating between PPA

subtypes, and both tCr and Glx could have utility as markers of PPA symptom severity.

However, further work in larger cohorts is needed to better understand the potential roles of tCr

and Glx in PPA development and progression.

Ethics Approval and Consent to Participate

The Johns Hopkins University Institutional Review Board (#NA_00071337) approved all

study procedures, and written informed consent was obtained from all participants.

Consent for Publication

All authors consent to the publication of this study.

Availability of Data and Material

The raw data supporting the conclusions of this manuscript will be made available by the

authors without undue reservation.

Competing Interests

All authors declare that they have no competing interests.

Funding

This work was supported by grants from the National Institute on Aging (K00 AG068440-

03 to KH, R00 AG062230 to GO, and R01 DC014475-05 and R01 AG068881-02 to KT) and

grants from the National Institute of Biomedical Imaging and Bioengineering (R01 EB016089 to

RE, and P41 EB031771).

Author Contributions

KH analyzed the MRS data, conducted all statistical analyses, created all figures and

supplemental material, and wrote the first draft of the manuscript. HZ, GO, SH, AH, and RAE

consulted on MRS data analyses and interpretation. HH contributed to manuscript writing and

results interpretation. OH, JG, AH, and KT facilitated MRS and behavioral data collection. KT

and RAE designed the project and led interpretation and discussion of the results. All authors

participated in revision of the manuscript.

Acknowledgements

The authors also wish to thank all of the participants who volunteered their time, without

whom this project would not have been possible.

Abbreviations

PPA: Primary progressive aphasia

lvPPA: logopenic variant PPA

nfvPPA: non-fluent variant PPA

svPPA: semantic variant PPA

MRS: magnetic resonance spectroscopy

IFG: inferior frontal gyrus

SMC: sensorimotor cortex

tNAA: total N-acetylaspartate

tCho: total choline

tCr: total creatine

Glx: glutamate+glutamine

GABA: gamma-aminobutyric acid

AD: Alzheimer's disease

TE: echo time

PRESS: Point RESolved Spectroscopy

NAAG: N-acetylaspartylglutamate

PCh: phosphocholine

GPC: glycerophosphocholine

MEGA-PRESS: MEscher–GArwood Point RESolved Spectroscopy

MCI: mild cognitive impairment

tDCS: transcranial direct current stimulation

FTD-CDR: FrontoTemporal Dementia Clinical Dementia Rating Scale

MPRAGE: magnetization-prepared rapid gradient-echo

HSVD: Hankel singular value decomposition

MMs: macromolecules

Cr: creatine

PCr: phosphocreatine

ATP: adenosine triphosphate

ADP: adenosine diphosphate

AGAT: glycine amidinotransferase

GAMT: guanidinoacetate methyltransferase

SNPH: syntaphilin

References

1. Gorno-Tempini ML, Hillis AE, Weintraub S, Kertesz A, Mendez M, Cappa SF, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;76(11):1006–14.

2. Mesulam M. Slowly progressive aphasia without generalized dementia. Ann Neurol Off J Am Neurol Assoc Child Neurol Soc. 1982;11(6):592–8.

3. Grossman M. Primary progressive aphasia: clinicopathological correlations. Nat Rev Neurol. 2010;6(2):88–97.

4. Hsiung GYR, Feldman HH. GRN frontotemporal dementia. GeneReviews. 2020;

5. Pagnoni I, Gobbi E, Premi E, Borroni B, Binetti G, Cotelli M, et al. Language training for oral and written naming impairment in primary progressive aphasia: A review. Transl Neurodegener. 2021;10(1):1–34.

6. Cotelli M, Manenti R, Ferrari C, Gobbi E, Macis A, Cappa SF. Effectiveness of language training and non-invasive brain stimulation on oral and written naming performance in Primary Progressive Aphasia: A meta-analysis and systematic review. Neurosci Biobehav Rev. 2020;108:498–525.

7. Tsapkini K, Webster KT, Ficek BN, Desmond JE, Onyike CU, Rapp B, et al. Electrical brain stimulation in different variants of primary progressive aphasia: A randomized clinical trial. Alzheimers Dement Transl Res Clin Interv. 2018;4:461–72.

8. Rogalski E, Cobia D, Martersteck A, Rademaker A, Wieneke C, Weintraub S, et al. Asymmetry of cortical decline in subtypes of primary progressive aphasia. Neurology. 2014;83(13):1184–91.

9. Mesulam M, Wicklund A, Johnson N, Rogalski E, Léger GC, Rademaker A, et al. Alzheimer and frontotemporal pathology in subsets of primary progressive aphasia. Ann Neurol Off J Am Neurol Assoc Child Neurol Soc. 2008;63(6):709–19.

10. Rabinovici GD, Jagust WJ, Furst AJ, Ogar JM, Racine CA, Mormino EC, et al. Aβ amyloid and glucose metabolism in three variants of primary progressive aphasia. Ann Neurol. 2008;64(4):388–401.

11. Josephs KA, Duffy JR, Strand EA, Whitwell JL, Layton KF, Parisi JE, et al. Clinicopathological and imaging correlates of progressive aphasia and apraxia of speech. Brain. 2006;129(6):1385–98.

12. Knibb JA, Xuereb JH, Patterson K, Hodges JR. Clinical and pathological characterization of progressive aphasia. Ann Neurol. 2006;59(1):156–65.

13. Davies RR, Hodges JR, Kril JJ, Patterson K, Halliday GM, Xuereb JH. The pathological basis of semantic dementia. Brain. 2005;128(9):1984–95.

14. Hodges JR, Davies RR, Xuereb JH, Casey B, Broe M, Bak TH, et al. Clinicopathological correlates in frontotemporal dementia. Ann Neurol. 2004;56(3):399–406.

15. Nestor PJ, Balan K, Cheow HK, Fryer TD, Knibb JA, Xuereb JH, et al. Nuclear imaging can
predict pathologic diagnosis in progressive nonfluent aphasia. Neurology. 2007;68(3):238–
9.

16. Bottomley P. Selective volume method for performing localized NMR spectroscopy.
US4480228A, 1982.

17. Rae CD. A guide to the metabolic pathways and function of metabolites observed in human
brain 1H magnetic resonance spectra. Neurochem Res. 2014;39(1):1–36.

18. Cleeland C, Pipingas A, Scholey A, White D. Neurochemical changes in the aging brain: A
systematic review. Neurosci Biobehav Rev. 2019;98:306–19.

19. Choi IY, Andronesi OC, Barker P, Bogner W, Edden RA, Kaiser LG, et al. Spectral editing in
1H magnetic resonance spectroscopy: Experts' consensus recommendations. NMR
Biomed. 2021;34(5):e4411.

20. Harris AD, Saleh MG, Edden RA. Edited 1H magnetic resonance spectroscopy in vivo:
Methods and metabolites. Magn Reson Med. 2017;77(4):1377–89.

21. Mescher M, Merkle H, Kirsch J, Garwood M, Gruetter R. Simultaneous in vivo spectral
editing and water suppression. NMR Biomed Int J Devoted Dev Appl Magn Reson Vivo.
1998;11(6):266–72.

22. Chiu PW, Mak HKF, Yau KKW, Chan Q, Chang RCC, Chu LW. Metabolic changes in the
anterior and posterior cingulate cortices of the normal aging brain: proton magnetic
resonance spectroscopy study at 3 T. Age. 2014;36(1):251–64.

23. Gao F, Edden RA, Li M, Puts NA, Wang G, Liu C, et al. Edited magnetic resonance
spectroscopy detects an age-related decline in brain GABA levels. Neuroimage.
2013;78:75–82.

24. Haga KK, Khor YP, Farrall A, Wardlaw JM. A systematic review of brain metabolite
changes, measured with 1H magnetic resonance spectroscopy, in healthy aging. Neurobiol
Aging. 2009;30(3):353–63.

25. Oeltzschner G, Wijtenburg SA, Mikkelsen M, Edden RA, Barker PB, Joo JH, et al.
Neurometabolites and associations with cognitive deficits in mild cognitive impairment: a
magnetic resonance spectroscopy study at 7 Tesla. Neurobiol Aging. 2019;73:211–8.

26. Zeydan B, Deelchand DK, Tosakulwong N, Lesnick TG, Kantarci OH, Machulda MM, et al.
Decreased glutamate levels in patients with amnestic mild cognitive impairment: An
sLASER proton MR spectroscopy and PiB-PET study. J Neuroimaging. 2017;27(6):630–6.

27. Bai X, Edden RA, Gao F, Wang G, Wu L, Zhao B, et al. Decreased γ-aminobutyric acid
levels in the parietal region of patients with Alzheimer's disease. J Magn Reson Imaging.
2015;41(5):1326–31.

28. Rupsingh R, Borrie M, Smith M, Wells JL, Bartha R. Reduced hippocampal glutamate in
Alzheimer disease. Neurobiol Aging. 2011;32(5):802–10.

29. Wang H, Tan L, Wang HF, Liu Y, Yin RH, Wang WY, et al. Magnetic resonance
spectroscopy in Alzheimer's disease: systematic review and meta-analysis. J Alzheimers
Dis. 2015;46(4):1049–70.

30. Zhang N, Song X, Bartha R, Beyea S, D'Arcy R, Zhang Y, et al. Advances in high-field
magnetic resonance spectroscopy in Alzheimer's disease. Curr Alzheimer Res.
2014;11(4):367–88.

31. Huang W, Alexander GE, Chang L, Shetty HU, Krasuski JS, Rapoport SI, et al. Brain
metabolite concentration and dementia severity in Alzheimer's disease: a 1H MRS study.
Neurology. 2001;57(4):626–32.

32. Marjańska M, McCarten JR, Hodges JS, Hemmy LS, Terpstra M. Distinctive neurochemistry
in Alzheimer's Disease via 7 T in vivo magnetic resonance spectroscopy. J Alzheimers Dis.
2019;68(2):559–69.

33. Erickson KI, Weinstein AM, Sutton BP, Prakash RS, Voss MW, Chaddock L, et al. Beyond
vascularization: aerobic fitness is associated with N-acetylaspartate and working memory.
Brain Behav. 2012;2(1):32–41.

34. Gomar JJ, Gordon ML, Dickinson D, Kingsley PB, Uluǧ AM, Keehlisen L, et al. APOE
genotype modulates proton magnetic resonance spectroscopy metabolites in the aging
brain. Biol Psychiatry. 2014;75(9):686–92.

35. Kantarci K, Lowe V, Przybelski SA, Senjem ML, Weigand SD, Ivnik RJ, et al. Magnetic
resonance spectroscopy, β-amyloid load, and cognition in a population-based sample of
cognitively normal older adults. Neurology. 2011;77(10):951–8.

36. Porges EC, Woods AJ, Edden RA, Puts NA, Harris AD, Chen H, et al. Frontal gamma-
aminobutyric acid concentrations are associated with cognitive performance in older
adults. Biol Psychiatry Cogn Neurosci Neuroimaging. 2017;2(1):38–44.

37. Ross AJ, Sachdev PS, Wen W, Valenzuela MJ, Brodaty H. Cognitive correlates of 1H MRS
measures in the healthy elderly brain. Brain Res Bull. 2005;66(1):9–16.

38. Griffith HR, den Hollander JA, Okonkwo O, Evanochko WT, Harrell LE, Zamrini EY, et al.
Executive function is associated with brain proton magnetic resonance spectroscopy in
amnestic mild cognitive impairment. J Clin Exp Neuropsychol. 2007;29(6):599–609.

39. Lim TS, Hong YH, Choi JY, Kim HS, Moon SY. Functional investigation of bilateral posterior
cingulate gyri using multivoxel MR spectroscopy. Eur Neurol. 2012;67(5):279–86.

40. Riese F, Gietl A, Zölch N, Henning A, O'Gorman R, Kälin AM, et al. Posterior cingulate γ-
aminobutyric acid and glutamate/glutamine are reduced in amnestic mild cognitive
impairment and are unrelated to amyloid deposition and apolipoprotein E genotype.
Neurobiol Aging. 2015;36(1):53–9.

41. Murley AG, Tsvetanov KA, Rouse MA, Jones PS, Sværke K, Li W, et al. Proton magnetic
resonance spectroscopy in frontotemporal lobar degeneration-related syndromes.
Neurobiol Aging. 2022;111:64–70.

42. Harris AD, Wang Z, Ficek B, Webster K, Edden RA, Tsapkini K. Reductions in GABA
following a tDCS-language intervention for primary progressive aphasia. Neurobiol Aging.
2019;79:75–82.

43. Knopman DS, Kramer JH, Boeve BF, Caselli RJ, Graff-Radford NR, Mendez MF, et al.
Development of methodology for conducting clinical trials in frontotemporal lobar
degeneration. Brain. 2008;131(11):2957–68.

44. Tkáč I, Starčuk Z, Choi IY, Gruetter R. In vivo 1H NMR spectroscopy of rat brain at 1 ms
echo time. Magn Reson Med Off J Int Soc Magn Reson Med. 1999;41(4):649–56.

45. Harris AD, Puts NA, Barker PB, Edden RA. Spectral-editing measurements of GABA in the
human brain with and without macromolecule suppression. Magn Reson Med.
2015;74(6):1523–9.

46. Oeltzschner G, Zöllner HJ, Hui SC, Mikkelsen M, Saleh MG, Tapper S, et al. Osprey: Open-
source processing, reconstruction & estimation of magnetic resonance spectroscopy data.
J Neurosci Methods. 2020;343:108827.

47. Wilson M, Andronesi O, Barker PB, Bartha R, Bizzi A, Bolan PJ, et al. Methodological
consensus on clinical proton MRS of the brain: Review and recommendations. Magn
Reson Med. 2019;82(2):527–50.

48. Zöllner HJ, Považan M, Hui SC, Tapper S, Edden RA, Oeltzschner G. Comparison of
different linear-combination modeling algorithms for short-TE proton spectra. NMR
Biomed. 2021;34(4):e4482.

49. Zöllner HJ, Tapper S, Hui SC, Barker PB, Edden RA, Oeltzschner G. Comparison of linear
combination modeling strategies for edited magnetic resonance spectroscopy at 3 T. NMR
Biomed. 2022;35(1):e4618.

50. Barkhuijsen H, De Beer R, Van Ormondt D. Improved algorithm for noniterative time-domain
model fitting to exponentially damped magnetic resonance signals. J Magn Reson 1969.
1987;73(3):553–7.

51. Hui SC, Saleh M, Zoellner HJ, Oeltzschner G, Fan H, Li Y, et al. MRSCloud: a Cloud-based
MR Spectroscopy Tool for Basis Set Simulation. bioRxiv. 2022;

52. Ashburner J, Barnes G, Chen CC, Daunizeau J, Flandin G, Friston K, et al. SPM12 manual.
Wellcome Trust Cent Neuroimaging Lond UK. 2014;2464:4.

53. Klose U. In vivo proton spectroscopy in presence of eddy currents. Magn Reson Med.
1990;14(1):26–30.

54. Mikkelsen M, Tapper S, Near J, Mostofsky SH, Puts NA, Edden RA. Correcting frequency
and phase offsets in MRS data using robust spectral registration. NMR Biomed.
2020;33(10):e4368.

55. Deelchand DK, Marjańska M, Henry PG, Terpstra M. MEGA-PRESS of GABA+: influences
of acquisition parameters. NMR Biomed. 2021;34(5):e4199.

56. Porges EC, Woods AJ, Lamb DG, Williamson JB, Cohen RA, Edden RA, et al. Impact of
tissue correction strategy on GABA-edited MRS findings. Neuroimage. 2017;162:249–56.

57. Wansapura JP, Holland SK, Dunn RS, Ball Jr WS. NMR relaxation times in the human brain
at 3.0 tesla. J Magn Reson Imaging Off J Int Soc Magn Reson Med. 1999;9(4):531–8.

58. Gasparovic C, Song T, Devier D, Bockholt HJ, Caprihan A, Mullins PG, et al. Use of tissue
water as a concentration reference for proton spectroscopic imaging. Magn Reson Med Off
J Int Soc Magn Reson Med. 2006;55(6):1219–26.

59. Harris AD, Puts NA, Edden RA. Tissue correction for GABA-edited MRS: Considerations of
voxel composition, tissue segmentation, and tissue relaxations. J Magn Reson Imaging.
2015;42(5):1431–40.

60. Lin A, Andronesi O, Bogner W, Choi IY, Coello E, Cudalbu C, et al. Minimum reporting
standards for in vivo magnetic resonance spectroscopy (MRSinMRS): experts' consensus
recommendations. NMR Biomed. 2021;34(5):e4484.

61. R Core Team. R: A language and environment for statistical computing. [Internet]. Vienna,
Austria: R Foundation for Statistical Computing; 2021. Available from: https://www.R-
project.org/

62. RStudio Team. RStudio: Integrated Development Environment for R [Internet]. Boston, MA:
RStudio, PBC; 2021. Available from: http://www.rstudio.com/

63. Pinheiro JC, Bates DM. Theory and computational methods for linear mixed-effects models.
Mix-Eff Models -PLUS. 2000;57–96.

64. Hupfeld KE, Hyatt HW, Alvarez Jerez P, Mikkelsen M, Hass CJ, Edden RAE, et al. In vivo
brain glutathione is higher in older age and correlates with mobility. Cereb Cortex.
2021;31(10):4576–94.

65. McLeod AI, Xu C. bestglm: Best subset GLM. URL HttpCRAN R-Proj Orgpackage Bestglm.
2010;

66. Zhang Z. Variable selection with stepwise and best subset approaches. Ann Transl Med.
2016;4(7).

67. Bürklen TS, Schlattner U, Homayouni R, Gough K, Rak M, Szeghalmi A, et al. The creatine
kinase/creatine connection to alzheimer's disease: CK Inactivation, APP-CK complexes
and focal creatine deposits. J Biomed Biotechnol. 2006;2006.

68. Rackayova V, Cudalbu C, Pouwels PJ, Braissant O. Creatine in the central nervous system:
From magnetic resonance spectroscopy to creatine deficiencies. Anal Biochem.
2017;529:144–57.

69. Reyngoudt H, Claeys T, Vlerick L, Verleden S, Acou M, Deblaere K, et al. Age-related
differences in metabolites in the posterior cingulate cortex and hippocampus of normal
ageing brain: a 1H-MRS study. Eur J Radiol. 2012;81(3):e223–31.

70. Charlton RA, McIntyre DJO, Howe FA, Morris RG, Markus HS. The relationship between
white matter brain metabolites and cognition in normal aging: the GENIE study. Brain Res.
2007;1164:108–16.

71. Chang L, Ernst T, Poland RE, Jenden DJ. In vivo proton magnetic resonance spectroscopy
of the normal aging human brain. Life Sci. 1996;58(22):2049–56.

72. Pfefferbaum A, Adalsteinsson E, Spielman D, Sullivan EV, Lim KO. In vivo spectroscopic
quantification of the N-acetyl moiety, creatine, and choline from large volumes of brain gray
and white matter: Effects of normal aging. Magn Reson Med Off J Int Soc Magn Reson
Med. 1999;41(2):276–84.

73. Chang L, Ernst T, Witt MD, Ames N, Gaiefsky M, Miller E. Relationships among brain
metabolites, cognitive function, and viral loads in antiretroviral-naıve HIV patients.
Neuroimage. 2002;17(3):1638–48.

74. Chang L, Ernst T, Witt MD, Ames N, Walot I, Jovicich J, et al. Persistent brain abnormalities
in antiretroviral-naive HIV patients 3 months after HAART. Antivir Ther. 2003;8(1):17–26.

75. Smith CD, Landrum W, Carney JM, Landfield PW, Avison MJ. Brain creatine kinase with
aging in F-344 rats: analysis by saturation transfer magnetic resonance spectroscopy.
Neurobiol Aging. 1997;18(6):617–22.

76. Pettegrew JW, Panchalingam K, Klunk WE, McClure RJ, Muenz LR. Alterations of cerebral
metabolism in probable Alzheimer's disease: a preliminary study. Neurobiol Aging.
1994;15(1):117–32.

77. McIntyre DJ, Charlton RA, Markus HS, Howe FA. Long and short echo time proton magnetic
resonance spectroscopic imaging of the healthy aging brain. J Magn Reson Imaging Off J
Int Soc Magn Reson Med. 2007;26(6):1596–606.

78. Adhihetty PJ, Beal MF. Creatine and its potential therapeutic value for targeting cellular
energy impairment in neurodegenerative diseases. Neuromolecular Med. 2008;10(4):275–
90.

79. Oeltzschner G, Saleh MG, Rimbault D, Mikkelsen M, Chan KL, Puts NA, et al. Advanced
Hadamard-encoded editing of seven low-concentration brain metabolites: Principles of
HERCULES. Neuroimage. 2019;185:181–90.

80. Cheng XT, Sheng ZH. Developmental regulation of microtubule-based trafficking and
anchoring of axonal mitochondria in health and diseases. Dev Neurobiol. 2021;81(3):284–
99.

81. Kang JS, Tian JH, Pan PY, Zald P, Li C, Deng C, et al. Docking of axonal mitochondria by
syntaphilin controls their mobility and affects short-term facilitation. Cell. 2008;132(1):137–
48.

82. Andres-Benito P, Gelpi E, Povedano M, Ausin K, Fernandez-Irigoyen J, Santamaría E, et al.
Combined transcriptomics and proteomics in frontal cortex area 8 in frontotemporal lobar
degeneration linked to C9orf72 expansion. J Alzheimers Dis. 2019;68(3):1287–307.

83. Fukumitsu K, Fujishima K, Yoshimura A, Wu YK, Heuser J, Kengaku M. Synergistic action of dendritic mitochondria and creatine kinase maintains ATP homeostasis and actin dynamics in growing neuronal dendrites. J Neurosci. 2015;35(14):5707–23.

84. Morsci NS, Hall DH, Driscoll M, Sheng ZH. Age-related phasic patterns of mitochondrial maintenance in adult Caenorhabditis elegans neurons. J Neurosci. 2016;36(4):1373–85.

85. Vagnoni A, Bullock SL. A cAMP/PKA/Kinesin-1 axis promotes the axonal transport of mitochondria in aging Drosophila neurons. Curr Biol. 2018;28(8):1265-1272. e4.

86. Saunders DE, Howe FA, van den Boogaart A, Griffiths JR, Brown MM. Aging of the adult human brain: in vivo quantitation of metabolite content with proton magnetic resonance spectroscopy. J Magn Reson Imaging Off J Int Soc Magn Reson Med. 1999;9(5):711–6.

87. Ratai EM, Annamalai L, Burdo T, Joo CG, Bombardier JP, Fell R, et al. Brain creatine elevation and N-acetylaspartate reduction indicates neuronal dysfunction in the setting of enhanced glial energy metabolism in a macaque model of NeuroAIDS. Magn Reson Med. 2011;66(3):625–34.

88. Urenjak J, Williams SR, Gadian DG, Noble M. Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types. J Neurosci. 1993;13(3):981–9.

89. Kim G, Ahmadian SS, Peterson M, Parton Z, Memon R, Weintraub S, et al. Asymmetric pathology in primary progressive aphasia with progranulin mutations and TDP inclusions. Neurology. 2016;86(7):627–36.

90. Ohm DT, Kim G, Gefen T, Rademaker A, Weintraub S, Bigio EH, et al. Prominent microglial activation in cortical white matter is selectively associated with cortical atrophy in primary progressive aphasia. Neuropathol Appl Neurobiol. 2019;45(3):216–29.

91. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol. 2008;8(12):958–69.

92. Perry VH, Nicoll JA, Holmes C. Microglia in neurodegenerative disease. Nat Rev Neurol. 2010;6(4):193–201.

93. Rosen HJ, Allison SC, Ogar JM, Amici S, Rose K, Dronkers N, et al. Behavioral features in semantic dementia vs other forms of progressive aphasias. Neurology. 2006;67(10):1752–6.

94. Gomez-Tortosa E, Rigual R, Prieto-Jurczynska C, Mahillo-Fernandez I, Guerrero-Lopez R, Perez-Perez J, et al. Behavioral evolution of progressive semantic aphasia in comparison with nonfluent aphasia. Dement Geriatr Cogn Disord. 2016;41(1–2):1–8.

95. Liakakis G, Nickel J, Seitz R. Diversity of the inferior frontal gyrus—a meta-analysis of neuroimaging studies. Behav Brain Res. 2011;225(1):341–7.

96. Avgerinos KI, Spyrou N, Bougioukas KI, Kapogiannis D. Effects of creatine supplementation on cognitive function of healthy individuals: A systematic review of randomized controlled trials. Exp Gerontol. 2018;108:166–73.

97. Levin O, Weerasekera A, King BR, Heise KF, Sima DM, Chalavi S, et al. Sensorimotor
cortex neurometabolite levels as correlate of motor performance in normal aging: evidence
from a 1H-MRS study. NeuroImage. 2019;202:116050.

98. Zahr NM, Mayer D, Rohlfing T, Chanraud S, Gu M, Sullivan EV, et al. In vivo glutamate
measured with magnetic resonance spectroscopy: behavioral correlates in aging.
Neurobiol Aging. 2013;34(4):1265–76.

99. Murley AG, Rouse MA, Jones PS, Ye R, Hezemans FH, O'Callaghan C, et al. GABA and
glutamate deficits from frontotemporal lobar degeneration are associated with disinhibition.
Brain. 2020;143(11):3449–62.

100. Duffy SL, Lagopoulos J, Hickie IB, Diamond K, Graeber MB, Lewis SJ, et al. Glutathione
relates to neuropsychological functioning in mild cognitive impairment. Alzheimers Dement.
2014;10(1):67–75.

101. Deelchand DK, McCarten JR, Hemmy LS, Auerbach EJ, Eberly LE, Marjańska M.
Changes in the intracellular microenvironment in the aging human brain. Neurobiol Aging.
2020;95:168–75.

102. Marjańska M, Emir UE, Deelchand DK, Terpstra M. Faster metabolite 1H transverse
relaxation in the elder human brain. PloS One. 2013;8(10):e77572.

103. Marjańska M, McCarten JR, Hodges J, Hemmy LS, Grant A, Deelchand DK, et al. Region-
specific aging of the human brain as evidenced by neurochemical profiles measured
noninvasively in the posterior cingulate cortex and the occipital lobe using 1H magnetic
resonance spectroscopy at 7 T. Neuroscience. 2017;354:168–77.

834